Abstract: Occupancy in a vehicle is determined by maintaining a set of occupant regions detected in a video. An occupant region can be a bounding box around a face, and/or an occupied seat that does not overlap any bounding box. A count, specific to an occupant region, is set to zero when an overlap between the occupant region in a current frame in the video and a previous frame in the video, satisfies a first predetermined condition. When the overlap does not satisfy the first predetermined condition, the count which is specific to the occupant region is incremented and checked against a threshold in a second predetermined condition. When the count exceeds the threshold, that occupant region is removed from the set of occupant regions. The just-described operations are repeated, with additional occupant regions. A count of occupant regions currently in the set may be displayed or transmitted to a server.

Abstract: The present disclosure relates generally to methods for doing business by using one or more biomarkers (e.g., a subject's genetic polymorphisms) to improve the research, development, testing, commercialization and/or marketing of a drug by identifying those subjects for whom the particular drug is likely to be more effective.

Abstract: Methods and apparatus for determining phase fractions (relative concentrations) within a multiphase fluid mixture, in the presence of an injected hydrate inhibitor. Combining this phase fraction information with a hydrate inhibitor injection rate (HIIR) enables resolving oil and water flow rates for the phase fractions. The liquid flow rates and a total combined flow rate of the fluid mixture—determined based on a differential pressure of the fluid mixture through a given area—enable resolving a gas flow rate.

Abstract: Methods, reagents and kits are provided for predicting whether an individual suffering from an antibody dependent cell-mediated cytotoxicity (ADCC)-treatable disease is responsive to an antibody maintenance therapy. The methods, reagents, and kits find a number of uses, including, for selecting individuals who will be responsive for treatment with an antibody maintenance therapy, for determining the appropriate maintenance therapy for an individual suffering from an ADCC-treatable disease, for determining the optimal regimen for antibody maintenance therapy, and for treating an individual with an antibody maintenance therapy based on stratification into responsive groups.

Abstract: Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on an Fc?RIIA polymorphism, or an Fc?RIIIA polymorphism, or both an Fc?RIIA polymorphism and an Fc?RIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's Fc?RIIA polymorphism, or Fc?RIIIA polymorphism, or both the Fc?RIIA polymorphism and the Fc?RIIIA polymorphism.

Abstract: Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on a Fc?RIIA polymorphism, or a Fc?RIIIA polymorphism, or both an Fc?RIIA polymorphism and a Fc?RIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's Fc?RIIA polymorphism, or Fc?RIIIA polymorphism, or both the Fc?RIIA polymorphism and the Fc?RIIIA polymorphism.

Abstract: Methods and apparatus for determining phase fractions (relative concentrations) within a multiphase fluid mixture, in the presence of an injected hydrate inhibitor. Combining this phase fraction information with a hydrate inhibitor injection rate (HIIR) enables resolving oil and water flow rates for the phase fractions. The liquid flow rates and a total combined flow rate of the fluid mixture—determined based on a differential pressure of the fluid mixture through a given area—enable resolving a gas flow rate.

Abstract: Methods and materials are provided for selecting and/or treating a subject based on a Fc?RIIA polymorphism, or a Fc?RIIB polymorphism, or both an Fc?RIIA polymorphism and a Fc?RIIB polymorphism, for treatment with a therapy including an antibody therapy such as rituximab. Methods are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's Fc?RIIA polymorphism, or Fc?RIIB polymorphism, or both the Fc?RIIA polymorphism and the Fc?RIIB polymorphism.

Abstract: The present disclosure relates generally to methods for doing business by using one or more biomarkers (e.g., a subject's genetic polymorphisms) to improve the research, development, testing, commercialization and/or marketing of a drug by identifying those subjects for whom the particular drug is likely to be more effective.

Abstract: Methods and apparatus enable measuring flow of a fluid within a conduit. For example, flowmeters may measure the velocity of production fluid flowing through production pipe of an oil/gas well. The flowmeters rely on detection of pressure variations generated as a result of a backward-facing step as a basis for flow measurement calculations. Pressure sensing occurs away from the step in a direction of the flow of the fluid in an enhanced turbulence region of the flowmeter where the inner diameter remains enlarged as a result of the step.

Abstract: Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on a Fc?RIIA polymorphism, or a Fc?RIIIA polymorphism, or both an Fc?RIIA polymorphism and a Fc?RIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's Fc?RIIA polymorphism, or Fc?RIIIA polymorphism, or both the Fc?RIIA polymorphism and the Fc?RIIIA polymorphism.

Abstract: Methods and apparatus enable measuring flow of a fluid within a conduit. For example, flowmeters may measure the velocity of production fluid flowing through production pipe of an oil/gas well. The flowmeters rely on detection of pressure variations generated as a result of a backward-facing step as a basis for flow measurement calculations. Pressure sensing occurs away from the step in a direction of the flow of the fluid in an enhanced turbulence region of the flowmeter where the inner diameter remains enlarged as a result of the step.

Abstract: Methods and apparatus enable measuring flow of a fluid within a conduit. For example, flowmeters may measure the velocity of production fluid flowing through production pipe of an oil/gas well. The flowmeters rely on detection of pressure variations generated as a result of a backward-facing step as a basis for flow measurement calculations. Pressure sensing occurs away from the step in a direction of the flow of the fluid in an enhanced turbulence region of the flowmeter where the inner diameter remains enlarged as a result of the step.

Abstract: Methods and apparatus enable measuring flow of a fluid within a conduit. For example, flowmeters may measure the velocity of production fluid flowing through production pipe of an oil/gas well. The flowmeters rely on detection of pressure variations generated as a result of a backward-facing step as a basis for flow measurement calculations. Pressure sensing occurs away from the step in a direction of the flow of the fluid in an enhanced turbulence region of the flowmeter where the inner diameter remains enlarged as a result of the step.

Abstract: The present invention relates to methods of making and using chimeric antibody molecules comprised of at least two domains, namely RAF, and IAF, linked by a flexible peptide linker.